Collateral damage: Toxic effects of targeted antiangiogenic therapies in ovarian cancer

The Lancet Oncology

Volumn 11, Issue 5, 2010, Pages 465-475

  Stone, Rebecca L ^a   Sood, Anil K ^a   Coleman, Robert L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BIBF 1120; CARBOPLATIN; CEDIRANIB; CLOBETASOL; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; FOSBRETABULIN; GEMCITABINE; IMATINIB; LOW MOLECULAR WEIGHT HEPARIN; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; WARFARIN; ANTINEOPLASTIC AGENT; HYBRID PROTEIN; MONOCLONAL ANTIBODY;

ANTIANGIOGENIC THERAPY; BLEEDING; BRAIN HEMORRHAGE; BRAIN METASTASIS; BREAST CANCER; CARDIOTOXICITY; CLINICAL TRIAL; COLLATERAL CIRCULATION; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DYSPEPSIA; ENDOCRINE DISEASE; ENTEROCUTANEOUS FISTULA; EPISTAXIS; ERYTHEMA; ESOPHAGITIS; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; GINGIVA BLEEDING; HAIR DISCOLORATION; HAND FOOT SYNDROME; HEART DISEASE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEMATURIA; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOTHYROIDISM; INTESTINE FISTULA; INTESTINE ISCHEMIA; INTESTINE PERFORATION; KIDNEY CARCINOMA; LEUKOCYTOCLASTIC VASCULITIS; LIVER TOXICITY; LOW DRUG DOSE; LUNG EMBOLISM; MACULOPAPULAR RASH; ODYNOPHAGIA; OVARY CANCER; PANCREATITIS; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROTEINURIA; QT PROLONGATION; REVIEW; SEBORRHEIC DERMATITIS; SIDE EFFECT; SKIN TOXICITY; SOLID TUMOR; THROMBOEMBOLISM; THYROID DISEASE; TUMOR VASCULARIZATION; VAGINA DISEASE; VENOUS THROMBOEMBOLISM; CARDIOVASCULAR DISEASE; FEMALE; GASTROINTESTINAL DISEASE; OVARY TUMOR; SKIN DISEASE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; ENDOCRINE SYSTEM DISEASES; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; OVARIAN NEOPLASMS; RECOMBINANT FUSION PROTEINS; SKIN DISEASES;

EID: 77952314572     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70362-6     Document Type: Review

References (108)

1. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007, 25:5180-5186.
2. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007, 25:5165-5171.
3. Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2006, 102:140-144.
4. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004, 291:2441-2447.
5. Campos SM, Dizon DS, Cannistra SA, et al. Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarian and müllerian cancers. Proc Am Soc Clin Oncol 2007, 25. abstr 5517.
6. Micha JP, Goldstein BH, Rettenmaier MA, et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 2007, 17:771-776.
7. Penson RT, Cannistra SA, Seiden MV, et al. Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors. Proc Am Soc Clin Oncol 2006, 24. abstr 5020.
8. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
9. McGonigle KF, Muntz HG, Vuky JL, et al. Phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian cancer or peritoneal cancer (OC). Proc Am Soc Clin Oncol 2008, 26. abstr 5551.
10. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008, 26:76-82.
11. Richardson DL, Backes FJ, Seamon LG, et al. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol 2008, 111:461-466.
12. Nimeiri HS, Oza AM, Morgan RJ, et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2008, 110:49-55.
13. Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008, 26:3709-3714.
14. Tew WP, Colombo N, Ray-Coquard I, et al. VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study. Proc Am Soc Clin Oncol 2007, 25. abstr 5508.
15. Moroney J, Sood AK, Coleman RL Aflibercept in epithelial ovarian carcinoma. Future Oncol 2009, 5:591-600.
16. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008, 13:1084-1096.
17. Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 2007, 1(suppl 2):41-54.
18. Biagi JJ, Oza AM, Grimshaw R, et al. A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma-NCIC CTG IND 185. Proc Am Soc Clin Oncol 2008, 26. abstr 5522.
19. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005, 23:965-972.
20. Matei D, Sill MW, DeGeest K, Bristow RE Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. Proc Am Soc Clin Oncol 2008, 26. abstr 5537.
21. Welch S, Hirte H, Schilder RJ, et al. Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: a PMH phase II consortium trial. Proc Am Soc Clin Oncol 2006, 24. abstr 5084.
22. Friedlander M, Hancock KC, Benigno B, et al. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: initial results of a phase II study. Proc Am Soc Clin Oncol 2007, 25. abstr 5561.
23. Matulonis UA, Berlin ST, Krasner CN, et al. Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer. Proc Am Soc Clin Oncol 2008, 26. abstr 5501.
24. Hirte HW, Vidal L, Fleming GF, et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago and California consortia trial. Proc Am Soc Clin Oncol 2008, 26. abstr 5521.
25. Matulonis UA, Berlin ST, Krasner CN, et al. Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer. Proc Am Soc Clin Oncol 2008, 26. abstr 5501.
26. Kuenen B, Ruijter R, Hoekman K, et al. Dose finding study of SU6668 given thrice daily by oral route under fed conditions in patients with advanced malignancies. Proc Am Soc Clin Oncol 2002, 21. abstr 437.
27. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005, 16:1391-1397.
28. Yap TA, Carden CP, Kaye SB Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009, 9:167-181.
29. Jameson MB, Thompson PI, Baguley BC, et al. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 2003, 88:1844-1850.
30. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002, 62:3408-3416.
31. Rustin GJ, Bradley C, Galbraith S, et al. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 2003, 88:1160-1167.
32. Bilenker JH, Flaherty KT, Rosen M, et al. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res 2005, 11:1527-1533.
33. Delmonte A, Del Conte G, Sessa C, et al. Results from a phase 1/2 study of volociximab in combination with liposomal doxorubicin in relapsed advanced epithelial ovarian and primary peritoneal carcinoma. Proc Am Soc Clin Oncol 2008, 26. abstr 16527.
34. Gutheil JC, Campbell TN, Pierce PR, et al. Phase I study of vitaxin, an anti-angiogenic humanized monoclonal antibody to vascular integrin avB3. Proc Am Soc Clin Oncol 1998, 17. abstr 832.
35. van Heeckeren WJ, Ortiz J, Cooney MM, Remick SC Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?. J Clin Oncol 2007, 25:2993-2995.
36. Gressett SM, Shah SR Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 2009, 43:490-501.
37. Wright JD, Secord AA, Numnum TM, et al. A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. Int J Gynecol Cancer 2008, 18:400-406.
38. Chura JC, Van Iseghem K, Downs LS, Carson LF, Judson PL Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 2007, 107:326-330.
39. Friberg G, Oza AM, Morgan RJ, Vokes EE, Gandara DR, Fleming GF Bevacizumab (B) plus erlotinib (E) for patients (pts) with recurrent ovarian (OC) and fallopian tube (FT) cancer: preliminary results of a multi-center phase II trial. Proc Am Soc Clin Oncol 2006, 24. abstr 5018.
40. Herzog TJ, Spirtos NM, Hines JF, et al. Preliminary safety and efficacy results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. Proc Am Soc Clin Oncol 2007, 25. abstr 5518.
41. Cohn DE, Valmadre S, Resnick KE, Eaton LA, Copeland LJ, Fowler JM Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol 2006, 102:134-139.
42. Asmis TR, Chung KY, Teitcher JB, Kelsen DP, Shah MA Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity. Invest New Drugs 2008, 26:95-96.
43. Konner JA, Fallon K, Pezzuli S, et al. Phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel (Tax), IP cisplatin (Cis), and IV bevacizumab (Bev) as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer. Proc Am Soc Clin Oncol 2007, 25:5523.
44. Rustin GJ, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003, 21:2815-2822.
45. Zweifel M, Jayson G, Reed N, et al. Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: final phase II trial results. Proc Am Soc Clin Oncol 2009, 27. abstr 5502.
46. Eskens FA, Verweij J The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors: a review. Eur J Cancer 2006, 42:3127-3139.
47. Laurie SA, Gauthier I, Arnold A, et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2008, 26:1871-1878.
48. Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009, 20:807-815.
49. Porta C, Paglino C, Imarisio I, Bonomi L Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 2007, 7:127-134.
50. Gordon MS, Cunningham D Managing patients treated with bevacizumab combination therapy. Oncology 2005, 69(suppl 3):25-33.
51. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
52. Dirix LY, Maes H, Sweldens C Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors. Ann Oncol 2007, 18:1121-1122.
53. Cockcroft J Nebivolol: a review. Expert Opin Pharmacother 2004, 5:893-899.
54. Widakowich C, de Castro G, de Azambuja E, Dinh P, Awada A Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007, 12:1443-1455.
55. Langenberg M, van Herpen CM, De Bono JS, et al. Optimal management of emergent hypertension during treatment with a VEGF signaling inhibitor: a randomized phase II study of cediranib. Proc Am Soc Clin Oncol 2008, 26. abstr 3555.
56. Ostendorf T, Kunter U, Eitner F, et al. VEGF(165) mediates glomerular endothelial repair. J Clin Invest 1999, 104:913-923.
57. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008, 358:1129-1136.
58. Lenihan DJ Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?. J Clin Oncol 2008, 26:5154-5155.
59. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002, 20:1215-1221.
60. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007, 370:2011-2019.
61. Khakoo AY, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008, 112:2500-2508.
62. Elliott P Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol 2006, 33(suppl 8):2-7.
63. Force T, Krause DS, Van Etten RA Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007, 7:332-344.
64. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008, 26:5204-5212.
65. Cooney MM, Radivoyevitch T, Dowlati A, et al. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 2004, 10:96-100.
66. Grossmann M, Premaratne E, Desai J, Davis ID Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 2008, 69:669-672.
67. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004, 109:3122-3131.
68. Demetri GD Structural reengineering of imatinib to decrease cardiac risk in cancer therapy. J Clin Invest 2007, 117:3650-3653.
69. Tateo S, Mereu L, Salamano S, et al. Ovarian cancer and venous thromboembolic risk. Gynecol Oncol 2005, 99:119-125.
70. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007, 99:1232-1239.
71. Wright JD, Hagemann A, Rader JS, et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 2006, 107:83-89.
72. Holash J, Thurston G, Rudge JS, et al. Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents. Cancer Metastasis Rev 2006, 25:243-252.
73. Evans T, Valle J, Berlin J, et al. Interim results from a phase II study of volociximab in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (MPC). Gastrointestinal Cancers Symposium 2008, abstr 142.
74. Hersey P, Sosman J, O'Day S, et al. A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, ± dacarbazine (DTIC) in patients with metastatic melanoma (MM). Proc Am Soc Clin Oncol 2005, 23. abstr 7507.
75. Elice F, Rodeghiero F, Falanga A, Rickles FR Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol 2009, 22:115-128.
76. Hambleton J, Skillings J, Kabbinavar F, et al. Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). Proc Am Soc Clin Oncol 2005, 23. abstr 3554.
77. Hambleton J, Novotny WF, Hurwitz H Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. Proc Am Soc Clin Oncol 2004, 22:3528.
78. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002, 162:1729-1735.
79. Kilickap S, Abali H, Celik I Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003, 21:3542.
80. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
81. Limentani S, Just R, Purdham A, et al. A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus FOLFOX4 in patients (pts) with advanced solid tumors: preliminary results. Proc Am Soc Clin Oncol 2008, 26. abstr 3556.
82. Pouessel D, Culine S High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 2008, 53:376-381.
83. Drevs J, Siegert P, Medinger M, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007, 25:3045-3054.
84. Sugrue M, Kozloff M, Hainsworth J, et al. Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. Proc Am Soc Clin Oncol 2006, 24. abstr 3535.
85. Rutkowski P, Ruka W Emergency surgery in the era of molecular treatment of solid tumours. Lancet Oncol 2009, 10:157-163.
86. Hedrick E, Kozloff M, Hainsworth J, et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE). Proc Am Soc Clin Oncol 2006, 24. abstr 3536.
87. Colombo N, Mangili G, Mammoliti S, et al. Aflibercept (VEGF Trap) for advanced epithelial ovarian cancer (EOC) patients (pts) with symptomatic malignant ascites: Preliminary results of a pilot study. Proc Am Soc Clin Oncol 2008, 26. abstr 14598.
88. Sfakianos GP, Numnum TM, Halverson CB, Panjeti D, Kendrick JEt, Straughn JM The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study. Gynecol Oncol 2009, 114:424-426.
89. Simpkins F, Belinson JL, Rose PG Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol 2007, 107:118-123.
90. Ridruejo E, Cacchione R, Villamil AG, Marciano S, Gadano AC, Mando OG Imatinib-induced fatal acute liver failure. World J Gastroenterol 2007, 13:6608-7111.
91. Amar S, Wu KJ, Tan WW Sorafenib-induced pancreatitis. Mayo Clin Proc 2007, 82:521.
92. Badgwell BD, Camp ER, Feig B, et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 2008, 19:577-582.
93. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005, 91:173-180.
94. Han ES, Monk BJ What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?. Gynecol Oncol 2007, 105:3-6.
95. Berry S, Michael M, Kretzschmar A, et al. Lack of effect of starting bevacizumab shortly after venous access device implantation on wound healing/bleeding complications: preliminary results from first BEAT. Gastrointestinal Cancers Symposium 2006, abstr 245.
96. Ledermann JA, Rustin GJ, Hackshaw A, et al. A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC). Proc Am Soc Clin Oncol 2009, 27. abstr 5501.
97. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005, 92:1855-1861.
98. Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008, 158:592-596.
99. Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009, 15:1411-1416.
100. Galan Brotons A, Borras-Blasco J, Rosique-Robles JD, Vicent Verge JM, Castera ME Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome. Clin Transl Oncol 2008, 10:844-846.
101. Chung NM, Gutierrez M, Turner ML Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib. Arch Dermatol 2006, 142:1510-1511.
102. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol, 23: 5235-46.
103. Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 2007, 72:152-159.
104. Strumberg D, Awada A, Hirte H, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome?. Eur J Cancer 2006, 42:548-556.
105. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007, 99:81-83.
106. Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006, 145:660-664.
107. Billemont B, Medioni J, Taillade L, et al. Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br J Cancer 2008, 99:1380-1382.
108. Gatenby RA A change of strategy in the war on cancer. Nature 2009, 459:508-509.